Accelerated Approval: How The Aduhelm Probes Will, And Won’t, Impact The Debate

Even as the US FDA can expect to be put through the ringer with the congressional and HHS Inspector General probes, the process could have some upsides for the agency, according to former officials who have been through such scrutiny.

FDA under OIG microscope (design by Nielsen Hobbs)
FDA is undergoing two reviews related to its controversial approval of Biogen’s Aduhelm. • Source: Nielsen Hobbs; the Pink Sheet | Alamy image

More from US FDA

More from Agency Leadership